Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

486 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Podzamczer D, Imaz A, Lopez-Lirola A, Knobel H, Masiá M, Fanciulli C, Hernández C, Lagarde M, Gutierrez A, Curran A, Morano L, Montero-Alonso M, Troya J, Rigo R, Casadellà M, Navarro-Alcaraz A, Ardila F, Parera M, Bernal E, Echeverria P, Estrada V, Hidalgo-Tenorio C, Macias J, Prieto P, Portilla J, Valencia E, Vivancos MJ, Rivero A. Podzamczer D, et al. Among authors: macias j. J Antimicrob Chemother. 2023 Nov 6;78(11):2696-2701. doi: 10.1093/jac/dkad285. J Antimicrob Chemother. 2023. PMID: 37725999 Clinical Trial.
Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
Pineda JA, Santos J, Rivero A, Abdel-Kader L, Palacios R, Camacho A, Lozano F, Macías J; Liverey Study Investigator Team. Pineda JA, et al. Among authors: macias j. J Antimicrob Chemother. 2008 Apr;61(4):925-32. doi: 10.1093/jac/dkn045. Epub 2008 Feb 14. J Antimicrob Chemother. 2008. PMID: 18276600
Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.
Macías J, Viloria MM, Rivero A, de los Santos I, Márquez M, Portilla J, Di Lello F, Camacho A, Sanz-Sanz J, Ojeda G, Mata R, Gómez-Mateos J, Pineda JA; FIBROCEL study group. Macías J, et al. Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):2083-8. doi: 10.1007/s10096-012-1546-5. Epub 2012 Jan 19. Eur J Clin Microbiol Infect Dis. 2012. PMID: 22258426
HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy.
Frías M, Rodríguez-Cano D, Cuenca-López F, Macías J, Gordon A, Manzanares-Martín B, Pineda JA, Camacho Á, Torre-Cisneros J, Peña J, Rivero-Juárez A, Rivero A. Frías M, et al. Among authors: macias j. Pharmacogenomics J. 2017 Dec;17(6):551-555. doi: 10.1038/tpj.2016.42. Epub 2016 May 31. Pharmacogenomics J. 2017. PMID: 27241060
HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients.
Frías M, Rodríguez-Cano D, Cuenca-López F, Macías J, Gordon A, Manzanares-Martín B, Pineda JA, Camacho Á, Torre-Cisneros J, Peña J, Rivero-Juárez A, Rivero A. Frías M, et al. Among authors: macias j. Pharmacogenomics J. 2017 Dec;17(6):479-480. doi: 10.1038/tpj.2016.80. Epub 2016 Oct 25. Pharmacogenomics J. 2017. PMID: 27779247 No abstract available.
486 results